Nadine Fradet

• Led biology efforts across two drug discovery programs, shaping strategic direction and delivering critical data to support lead optimization. • Cooperated closely with chemistry, DMPK, and external collaborators to drive integrated project success. • Designed and implemented innovative research tools and disease-relevant models to accelerate multiple drug discovery programs. • Played a key role in VENT-03 program; assembling a robust preclinical package and oversaw Phase I clinical pharmacodynamic studies. • Managed and mentored biologists, cultivating a collaborative, high-performance scientific environment. Key Achievements: • Designed and established a skin biopsy-based disease model supporting VENT-03 proof-of-concept and IND-enabling studies. • Successfully transferred the VENT-03 pharmacodynamic (PD) assay to a CRO in the Netherlands; oversaw technical transition, data analysis, and interpretation. • Authored and implemented multiple SOPs across Ventus’ research organization to standardize workflows and ensure compliance. • Formulated novel hypothesis and developed in vitro tools to experimentally validate them.

• Designed and validated cellular assays for client-based drug discovery projects. • Supported target validation, lead identification and lead optimization (SAR). • Presented experimental plans and data to clients, ensuring scientific rigor and adherence to timelines. • Worked cross-functionally with chemistry and DMPK teams across multiple programs.

• Identified novel therapeutic targets and biomarkers for the treatment and early diagnosis of Acute Lymphoblastic Leukemia using genome-wide CRISPR-Cas9 dropout screening and high-throughput sequencing. • Purified biologics (antibodies) using various protein purification methodologies.

• Developed and validated HTS-compatible cellular assays for the discovery of small molecules targeting kidney diseases (ADPKD). • Built primary renal cell platforms and 3D in vitro models to assess compound efficacy in disease-relevant contexts. • Developed an improved CRISPR-Cas9 strategy and developed secondary assays to support lead identification and validation. • Introduced novel strategies to improve assay robustness and increase translational relevance.

• Led the in vivo research group focusing on kidney disease therapeutics. • Developed and implemented preclinical kidney disease models, established experimental protocols, and led data analysis to support translational research. • Supported molecular and genomic research, contributing to SOP development and study optimization.

• Investigated DOCK180 and Rac signaling in cytoskeletal reorganization and cancer cell migration. • Supervised and trained students; contributed to grant writing and several publications.

Generated and validated large genomic deletions in murine embryonic stem cells to identify novel genes involved in hematopoietic differentiation